NCT04348695View on ClinicalTrials.gov

Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

April 12, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Coronavirus Infection
Interventions
DRUG

Ruxolitinib plus simvastatin

"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days"

OTHER

Standard of Care

Patients will receive treatment according to usual clinical practice in the participant site.

Trial Locations (1)

28050

Hospital Universitario Madrid Sanchinarro, Madrid

All Listed Sponsors
collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Fundación de investigación HM

OTHER

NCT04348695 - Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19. | Biotech Hunter | Biotech Hunter